Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gilead (GILD) is having a good run despite the volatility on a string of positive updates.

Gilead (GILD) Up 2.6% in 3 Months: Will the Momentum Continue?

Franklin Resources

FS KKR Capital Corp

Kohl's

New York Community Bancorp

Prudential Financial

Walgreens

Being a Wall Street analyst is sometimes like being the local meteorologist on TV.

7 Big Dividend Stocks Wall Street Hates That Investors Should Love Now

Gilead Sciences Inc (NASDAQ: GILD) ended in the green on Tuesday after a JPMorgan analyst turned bullish on the biopharmaceutical company. Gilead stock should be worth $80 a share Chriss Schott now rates this healthcare name at “overweight” and sees upside to $80 a share – about a 25% increase from here.

Gilead stock price ‘does not' reflect its oncology business: Analyst

A JPMorgan analyst upgraded shares of Gilead to Overweight from Neutral.

Gilead Has Growth Potential in HIV and Oncology Franchises, Analyst Says

Shares of Gilead Sciences Inc. GILD, +1.02% rallied 3.2% in premarket trading Tuesday, after the biopharmaceutical company was upgraded at J.P. Morgan, which cited greater clarity on the human immunodeficiency virus (HIV) IV franchise and an emerging and undervalued oncology, or cancer treatment franchise.

Gilead stock rallies after J.P. Morgan turns bullish, citing HIV and undervalued oncology businesses

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production. Viral vectors are key components needed to manufacture Kite's cell therapies to treat certain blood cancers. Kite is the only cell therapy company with in-house commercial and clinical trial viral vector manufacturing capabilities, au

Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product

Gilead Sciences has seen a solid second quarter, with non-Covid-19 related product sales being relatively strong. The company has been pursing some bolt-on deals in the meantime, nothing which moves the needle in a major way.

Gilead Sciences: Becoming A Cure

BioMarin Pharmaceutical

Pfizer

Could now be a good time to add these top biotech stocks to your October 2022 watchlist?

3 Biotech Stocks For Your October 2022 Watchlist

Chevron

Dow Inc

EPR Properties

Intel

LTC Properties

San Juan Basin Royalty Trust

The best safe monthly dividend stocks are remarkably compelling during the current market downturn. However, many top dividend stocks have also taken a sizeable hit in value over the past several months.

7 Monthly Dividend Stocks to Buy for Safety

A federal judge in New York has frozen the assets of dozens of people and entities accused of operating a massive nationwide scheme to distribute counterfeit bottles of Gilead Sciences Inc HIV drugs, including two alleged "kingpins."

Gilead widens battle against alleged counterfeit HIV drug ring

BioNTech SE

Moderna

Covid-related product sales helped make BioNTech SE ( BNTX , Financial), Moderna Inc. ( MRNA , Financial), Gilead Sciences Inc. ( GILD , Financial) and Regeneron Pharmaceuticals Inc. ( REGN , Financial) the most productive biopharma companies in 2021, according to a Fierce Pharma ranking.

Covid-Related Sales Boost BioNTech, Moderna and Gilead

AbbVie

These two biotechs already have a solid track record.

Got $1,000? 2 Stocks That Could Be Bargain Buys For 2022 and Beyond

We look at an overview of Gilead's HIV medication. Gilead currently pays a 4.52% dividend.

A Dive Into Gilead Sciences' New HIV Medication

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. today announced a new public-private initiative with the Partnership for Health Advancement in Vietnam (HAIVN), a collaboration between Brigham and Women's Hospital, Harvard Medical School and Beth Israel Deaconess Medical Center. This multi-year initiative will have a phased approach to help address barriers that limit viral hepatitis diagnosis and care at primary healthcare facilities in Vietnam and the Philippines, two countries wit

Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MiroBio, a privately held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for approximately $405 million in cash. The acquisition provides Gilead with MiroBio's proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio's lead

Gilead Sciences Completes Acquisition of MiroBio

Gilead's (GILD) COVID-19 treatment Veklury and CAR T-cell therapy Yescarta get positive CHMP recommendation for additional indications.

Gilead (GILD) Drugs Get Positive CHMP Opinion for Label Expansion

Gilead's (GILD) Veklury is now recommended by the WHO for use in both non-severe COVID-19 patients at the highest risk of hospitalization and those with severe COVID-19.

WHO Recommends Gilead's (GILD) Veklury for Severe COVID-19

A flurry of regulatory announcements relating to COVID treatments, vaccines and boosters dominated headlines on the pandemic Friday, with Europe now considering giving vaccines full marketing authorization to avoid having to review them every year.

Europe may give COVID vaccines full marketing authorization to avoid annual review, and WHO backs Gilead's Veklury for severe disease

Best Buy

Holly Energy Partners

LyondellBasell Industries

Altria

AT&T

Finding stocks that are trading down after the worst first half for the S&P 500 in over 50 years, and a third quarter that is rolling over big time, is not hard these days.

8 Stocks in the Penalty Box That Offer Big Upside and Passive Income Dividends as High as 9%

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Yescarta® (axicabtagene ciloleucel) for adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. If approved, Yescarta will be the fir

Kite's CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Gilead Sciences Inc. GILD, -0.28% said Friday the European regulator has adopted a positive opinion on extending the use of its COVID treatment Veklury for pediatric patients. The European Commission will review the recommendation, and if adopted, Veklury, also called remdesivir, could become the only authorized treatment for adolescents at high risk of developing severe disease and children with COVID who require supplemental oxygen.

EU regulator recommends extending Gilead's COVID treatment Veklury for use in pediatric patients

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion to extend the indication of Veklury® (remdesivir) for the treatment of pediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and are at increased risk of progressing to severe COVID-19 and pediatric patients (4 weeks of age and older and weighing at

CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19

Gilead Sciences Inc. GILD, -0.28% said late Thursday the World Health Organization expanded its recommended guide for the use of the biotech drug maker's COVID-19 treatment Veklury. In a statement, the company said WHO updated its guidelines to recommend the drug to treat patients with severe COVID, an expansion from simply "those with non-severe COVID-19 at the highest risk of hospitalization.

Gilead COVID-19 drug gets expanded WHO recommendation

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced updates to the World Health Organization's (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury® (remdesivir) for the treatment of patients with severe COVID-19 and continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization. The WHO conditional recommendation for Veklury's use in the treatment of patients w

WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline

Gilead Sciences, Inc. (NASDAQ:GILD ) Baird 2022 Global Healthcare Conference September 14, 2022 9:30 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Unidentified Analyst Good morning, everyone. Thank you for joining us our next fireside chat.

News for Gilead Sciences Stock (GILD)